Literature DB >> 10635329

Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC.

D E Feldman1, V Thulasiraman, R G Ferreyra, J Frydman.   

Abstract

von Hippel-Lindau (VHL) disease is caused by loss of function of the VHL tumor suppressor protein. Here, we demonstrate that the folding and assembly of VHL into a complex with its partner proteins, elongin B and elongin C (herein, elongin BC), is directly mediated by the chaperonin TRiC/CCT. Association of VHL with TRiC is required for formation of the VHL-elongin BC complex. A 55-amino acid domain of VHL is both necessary and sufficient for binding to TRiC. Importantly, mutation or deletion of this domain is associated with VHL disease. We identified two mutations that disrupt the normal interaction with TRiC and impair VHL folding. Our results define a novel role for TRiC in mediating oligomerization and suggest that inactivating mutations can impair polypeptide function by interfering with chaperone-mediated folding.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10635329     DOI: 10.1016/s1097-2765(00)80233-6

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  89 in total

1.  Structure of eukaryotic prefoldin and of its complexes with unfolded actin and the cytosolic chaperonin CCT.

Authors:  Jaime Martín-Benito; Jasminka Boskovic; Paulino Gómez-Puertas; José L Carrascosa; C Torrey Simons; Sally A Lewis; Francesca Bartolini; Nicholas J Cowan; José M Valpuesta
Journal:  EMBO J       Date:  2002-12-02       Impact factor: 11.598

2.  Eukaryotic chaperonin containing T-complex polypeptide 1 interacts with filamentous actin and reduces the initial rate of actin polymerization in vitro.

Authors:  Julie Grantham; Lloyd W Ruddock; Anne Roobol; Martin J Carden
Journal:  Cell Stress Chaperones       Date:  2002-07       Impact factor: 3.667

3.  TRiC/CCT cooperates with different upstream chaperones in the folding of distinct protein classes.

Authors:  Katja Siegers; Bettina Bölter; Juliane P Schwarz; Ulrike M K Böttcher; Suranjana Guha; F Ulrich Hartl
Journal:  EMBO J       Date:  2003-10-01       Impact factor: 11.598

4.  Structure of minimal tetratricopeptide repeat domain protein Tah1 reveals mechanism of its interaction with Pih1 and Hsp90.

Authors:  Beatriz Jiménez; Francisca Ugwu; Rongmin Zhao; Leticia Ortí; Taras Makhnevych; Antonio Pineda-Lucena; Walid A Houry
Journal:  J Biol Chem       Date:  2011-12-16       Impact factor: 5.157

5.  Proteomic dissection of the von Hippel-Lindau (VHL) interactome.

Authors:  Yanlai Lai; Meihua Song; Kevin Hakala; Susan T Weintraub; Yuzuru Shiio
Journal:  J Proteome Res       Date:  2011-10-11       Impact factor: 4.466

6.  Trivalent arsenic inhibits the functions of chaperonin complex.

Authors:  Xuewen Pan; Stefanie Reissman; Nick R Douglas; Zhiwei Huang; Daniel S Yuan; Xiaoling Wang; J Michael McCaffery; Judith Frydman; Jef D Boeke
Journal:  Genetics       Date:  2010-07-26       Impact factor: 4.562

7.  Molecular insight into the conformational dynamics of the Elongin BC complex and its interaction with HIV-1 Vif.

Authors:  Sean R Marcsisin; John R Engen
Journal:  J Mol Biol       Date:  2010-08-20       Impact factor: 5.469

8.  The molecular chaperone CCT modulates the activity of the actin filament severing and capping protein gelsolin in vitro.

Authors:  Andreas Svanström; Julie Grantham
Journal:  Cell Stress Chaperones       Date:  2015-09-12       Impact factor: 3.667

9.  Structural and functional insights into TRiC chaperonin from a psychrophilic yeast, Glaciozyma antarctica.

Authors:  Nur Athirah Yusof; Shazilah Kamaruddin; Farah Diba Abu Bakar; Nor Muhammad Mahadi; Abdul Munir Abdul Murad
Journal:  Cell Stress Chaperones       Date:  2019-01-16       Impact factor: 3.667

10.  Analysis of quality control substrates in distinct cellular compartments reveals a unique role for Rpn4p in tolerating misfolded membrane proteins.

Authors:  Meredith Boyle Metzger; Susan Michaelis
Journal:  Mol Biol Cell       Date:  2008-12-10       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.